Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises McKesson Corporation on Its Acquisition of RxCrossroads from CVS Health Corporation
Davis Polk is advising McKesson Corporation on its acquisition of RxCrossroads, a provider of tailored services to…
Allena Pharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of…
Omnicell, Inc. $125 Million SEC-Registered At-The-Market Offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Omnicell, Inc. of…
Ablynx NV $230 Million U.S. Initial Public Offering of ADSs and Listing on the NASDAQ
Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230…
Advanced Accelerator Applications $3.9 billion acquisition by Novartis
Davis Polk is advising Advanced Accelerator Applications S.A. on its $3.9 billion acquisition by Novartis. Entry into…
Davis Polk Advises ViewRay, Inc. on a $50 Million Direct Registered Equity Offering
Davis Polk advised ViewRay, Inc. in a direct registered offering of 8,382,643 shares of ViewRay’s common stock for proceeds…
Davis Polk Advises Auris Medical Holding AG on Its Registered Offering of Common Shares and Equity Line of Financing
Davis Polk advised Auris Medical Holding AG in connection with the SEC-registered offering of $1.5 million of its common…
Flexion Therapeutics, Inc. $122.4 Million Follow-On Offering
Davis Polk advised the representatives of the underwriters in connection with the $122.4 million public offering of 4…
Hologic, Inc. $350 Million Senior Notes Offering
Davis Polk advised the representative of the initial purchasers on a Rule 144A/Regulation S offering by Hologic, Inc…
Deciphera Pharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,500,000 shares of common stock of…